Impact of ankylosing spondylitis (AS) on social participation and reversibility by anti-TNF-a (adalimumab) therapy - AS participation study

niversiteit Maastricht0 个研究点目标入组 80 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- Have AS according to the New York criteria
•- Be under the care of a rheumatologist
•- Start TNF inhibitors (adalimumab) as being part of current practice
•- BASDAI score of 4 or higher.
•- All subjects must be recruited within a period of 1 (one) year from the start of the longitudinal study.

•- Have severe non-AS related co morbidity according to the diagnose treatment combination (DBC). Please note that this only applies for patients with a co-morbidity, by whom the treating doctor/rheumatologist decides they should not be included in the study because of health reasons. Patients who suffer from a co-morbidity without a non-immediate health risk will be included. Their situation will be assesses with the SQC questionnaire in order to correct for a confounding effect.
•- Have contra-indications (diagnosed by treating rheumatologist/specialist) for TNF inhibition
•- Do not understand the Dutch language
•- Do not have access to a computer with internet

发起方